Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters
/in Hyperthermia, International PublicationsTargeting cancer stem cells via dendritic-cell vaccination
/in Dendritic Cells, International PublicationsComplex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
/in Dendritic Cells, International PublicationsOptimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity
/in Dendritic Cells, International Publications, Multiple Myeloma[Immunotherapy with hyperthermia for advanced or recurrent breast cancer patients in whom standard therapy showed no effect or was refused]
/in Breast Cancer, Hyperthermia, International PublicationsAscorbic acid alleviates toxicity of paclitaxel without interfering with the anticancer efficacy in mice
/in International Publications, MicronutrientsSelenoprotein P status correlates to cancer-specific mortality in renal cancer patients
/in International Publications, MicronutrientsDendritic cell-based immunotherapy in mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer